Prospective observational study to investigate lipid-related residual risks for the patients with acute coronary syndrome who were administrated high-dose strong stati
- Conditions
- Acute myocardial infarction
- Registration Number
- JPRN-UMIN000051955
- Lead Sponsor
- Iwate Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 62
Not provided
(1) Cases who have a contraindication of rosuvastatin treatment (such as in patients receiving cyclosporine) or requires cautious administration (patients with hypothyroidism or patients planning to use fibrates other than fenofibrate). (2) Cases who have a side effects like muscle pain and poor tolerability to rosuvastatin oral administration. (3) Cases who have already used or have a plan to use other high cholesterol-improving medications (such as evolocumab or ezetimibe) during the observation period. (4) Cases of familial hypercholesterolemia. (5) Cases with chronic inflammatory diseases (autoimmune diseases) or ongoing cancer treatment. (6) Cases with impaired consciousness, general malaise, or severe mental disorders. (7) Other cases who are deemed inappropriate by the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The patients who fully achieved the guideline-recommended goal of lipid management, were defined as "achieved group". All the rest were defined as "unachieved group". Of them, incidence and relative factor of the unachieved group will be assessed in the present study.
- Secondary Outcome Measures
Name Time Method